{
    "ticker": "XNCR",
    "name": "Xencor, Inc.",
    "description": "Xencor, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment landscape for patients with cancer and autoimmune diseases through its innovative protein engineering technology. Founded in 1997 and headquartered in Monrovia, California, Xencor has developed a proprietary XmAb technology platform that enables the creation of engineered monoclonal antibodies with enhanced efficacy and specificity. The company focuses on developing its pipeline of drug candidates, which includes bispecific antibodies and engineered cytokines, aimed at addressing unmet medical needs. Xencor's lead product candidates include XmAb14045, a bispecific T cell engager for the treatment of hematologic malignancies, and XmAb7195, an anti-PD-1 monoclonal antibody for the treatment of solid tumors. The company's commitment to innovation is reflected in its partnerships with leading pharmaceutical companies, which leverage Xencor\u2019s unique technology to enhance their therapeutic offerings. Through its dedicated research and development efforts, Xencor is poised to make significant contributions to the field of immunotherapy and improve outcomes for patients suffering from serious diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Monrovia, California, USA",
    "founded": "1997",
    "website": "https://www.xencor.com",
    "ceo": "Armen A. Bitchatchian",
    "social_media": {
        "twitter": "https://twitter.com/XencorInc",
        "linkedin": "https://www.linkedin.com/company/xencor"
    },
    "investor_relations": "https://investors.xencor.com",
    "key_executives": [
        {
            "name": "Armen A. Bitchatchian",
            "position": "CEO"
        },
        {
            "name": "Kirk A. H. M. M. C. S. R. K. A. D. R. H. R. D.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "XmAb14045",
                "XmAb7195"
            ]
        },
        {
            "category": "Autoimmune Diseases",
            "products": [
                "XmAb20717"
            ]
        }
    ],
    "seo": {
        "meta_title": "Xencor, Inc. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore Xencor, Inc., a leader in biopharmaceutical innovation focused on cancer and autoimmune disease treatments. Learn about our advanced XmAb technology and product pipeline.",
        "keywords": [
            "Xencor",
            "Biotechnology",
            "Pharmaceuticals",
            "Cancer Treatment",
            "Autoimmune Diseases",
            "Immunotherapy"
        ]
    },
    "faq": [
        {
            "question": "What is Xencor known for?",
            "answer": "Xencor is known for its innovative protein engineering technology and development of monoclonal antibodies for cancer and autoimmune diseases."
        },
        {
            "question": "Who is the CEO of Xencor?",
            "answer": "Armen A. Bitchatchian is the CEO of Xencor, Inc."
        },
        {
            "question": "Where is Xencor headquartered?",
            "answer": "Xencor is headquartered in Monrovia, California, USA."
        },
        {
            "question": "What are Xencor's main products?",
            "answer": "Xencor's main products include XmAb14045 for hematologic malignancies and XmAb7195 for solid tumors."
        },
        {
            "question": "When was Xencor founded?",
            "answer": "Xencor was founded in 1997."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "BMY",
        "VRTX"
    ],
    "related_stocks": [
        "GILD",
        "CELG",
        "MRNA",
        "NVAX"
    ]
}